Hyperpure chlorine dioxide versus chlorhexidine in intra-oral halitosis (ODOR trial) – protocol of a double-blinded, double-arm, parallel non-inferiority pilot randomized controlled trial (2024)

Background

The prevalence of halitosis is approximately 31.8% and is constantly increasing [1]. Intra-oral halitosis (IOH) is the most common type of bad breath [2]. The main consequences of halitosis are feelings of inadequacy, depression, anxiety, sensitivity, anger, stress [3], and impaired oral health-related quality of life (OHRQoL) [4].

Mouthwashes are the subsequent treatment of IOH after toothbrushing and tongue cleaning [5,6,7,8]; however, guidelines for the management of IOH still do not exist. Several types of mouthwashes are available on the market. Although most of the currently used ones, such as those containing chlorhexidine or alcohol, are effective; however, they are not recommended for daily use due to their potential side effects [9] such as tooth discoloration [10], and false taste sensations [11]. Chlorhexidine is considered to be the gold standard mouthwash for its potent antimicrobial properties and effectiveness in reducing plaque and gingivitis [12]. However, when it comes to intra-oral halitosis, the evidence supporting the efficacy of chlorhexidine is still uncertain [13].

Mouthwashes containing chlorine dioxide (ClO₂) have a doubled effect of reducing IOH; they reduce the amount of bacteria together with the volatile sulfur compounds [14,15,16], which are the main components of IOH. Their main advantage is the lack of known side effects and efficacy in low concentrations [17]. Most ClO₂ mouthwashes contain a stabilized form of ClO₂ [18,19,20,21]. However, they are assumed to be less effective than hyperpure ClO₂ due to lower concentrations of active ClO₂ molecules and contamination with other ingredients [14, 22]. In an in vitro study, the hyperpure ClO₂ solution showed superior effectiveness to chlorhexidine against aerobic bacteria and Candida; furthermore, its biofilm-dissolving effect is significantly higher [23].

Several studies have already investigated stabilized ClO₂ mouthwashes in IOH [20, 24,25,26,27]; a meta-analysis [28] found them effective in halitosis compared to placebo. However, none of the previous studies have investigated the efficacy of a hyperpure version of ClO₂ in IOH compared to chlorhexidine, which indicates the relevance of this randomized controlled trial (RCT).

Objectives

We aim to investigate the effectiveness of hyperpure ClO₂ in IOH with organoleptic measurement as the primary endpoint.

We hypothesize that hyperpure ClO₂-containing mouthwash is non-inferior to gold standard chlorhexidine mouthwash in IOH, reducing the halitosis level measured by the organoleptic test score.

Trial design

This study protocol is designed as a pilot, single-center, double-blinded, parallel-group, double-armed RCT with a non-inferiority design. We plan to investigate the short-term effects over a 3-h period.

Study protocol development

The SC and ITAB members developed the first version of the trial protocol following the Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) 2013 Statement [29].

Study setting

The study will be performed with one urban center at the Department of Restorative Dentistry and Endodontics, Semmelweis University (Budapest, Hungary).

Eligibility criteria

Inclusion criteria

• ►Aged 18 or older

• ►Organoleptic test score (OLS) ≥ 2 for IOH (A trained dentist will perform the measurements.)

• ►Patients with at least 20 teeth.

• ►Eight hours of use of scented oral hygiene product, 4 h of eating, and 2 h of drinking restriction

• ►Restriction of alcohol, caffeine, perfume usage, and food intake with characteristic smell on the day of investigation

Exclusion criteria

• ►Medical history of systemic and infectious diseases (e.g., hepatitis, HIV, tuberculosis)

• ►Antibiotic use within a month before or during the study or any regular medication

• ►Extraoral halitosis (distinguished by observing the nasal breath)

• ►Eat foods linked to oral malodor (e.g., garlic) on the day before and on the day of sampling, as well as wear heavily fragrant cosmetics on that day

• ►Patients with removable dentures

• ►Smokers (cigars, cigarettes, pipes, chewing tobacco, e-cigarette, or vaping products used in the last month)

Interventions

The two arms will be the following:

1. 1.

   Hyperpure ClO₂ mouthwash (Solumium Coral®)

2. 2.

   Chlorhexidine mouthwash (Curasept ADS 220®)

Enrollment begins January 18, 2024.

We will perform randomization if eligibility criteria are fulfilled. After baseline data have been recorded, interventions will be performed.The test group will use a 25 ml 10-fold dilution of hyperpure 0.03% ClO₂ (Solumium Coral®, final concentration: 0.003%) [30], and the control group will use chlorhexidine-containing mouthwashes (Curasept ADS 220, 0.2%). Rinsing will last 2 × 15 s in both groups as recommended by the manufacturer (2 × 12.5 ml) [31]. Intervention and control mouthwashes will be portioned into equally dark glasses.

Outcomes

Primary outcome

The primary endpoint of the study will be the changes in organoleptic test scores as measured by a trained dentist with the gold standard 6-point (0–5) intensity scale [32].

Tests will be performed three times (Table1): at baseline, immediately after and 3 h after rinsing with mouthwash. Two changes will be measured between the following time points: 1) baseline - immediately after rinsing, and 2) baseline - 3 h later; as suggested by Yaegaki et al. in their halitosis research [33].

Secondary outcomes

1. 1.

   We plan to measure the changes in volatile sulfur compounds, such as hydrogen sulfide, methyl mercaptan, and dimethyl sulfide with gas chromatography-mass spectrometry (GC/MS) at the same time points as the primary endpoint. It is an instrumental technique comprising a gas chromatograph coupled to a mass spectrometer, which allows complex mixtures of chemicals to be separated, identified and quantified. Calibration will be performed with a gas mixture produced by Linde (100 ppb H₂S, 500 ppb CH₃SH, 1000 ppb (CH₃)₂S). Samples will be collected in Teflon-coated bags and delivered to the measurement site immediately after sampling.

2. 2.

   Self-perceived halitosis. We will collect these data on a visual analog scale (Slider (RedCAP), visual analog scale coded as values 0–100) at the time mentioned above.

3. 3.

   Side effects. (e.g., tooth discoloration, signs of allergic reactions, subjective experiences: unpleasant taste, false taste or burning sensation, pain, and changes in salivary flow).

Sample size

We plan to conduct a study with a sample exploratory nature because the specific intervention has not yet revealed data in IOH in the literature. In the pilot phase, 30 participants each will be investigated in two groups. Then, the results of the primary outcome are used for sample size estimation. If the pilot can be continued, we will use it as an interim analysis in our study.

Recruitment

The primary site of recruitment is the Education Center of the Faculty of Dentistry (Semmelweis University, Budapest, Hungary), which receives on average 10,179 patients per month. The trial will be advertised on posters and social media.

Assignment of interventions

Allocation & blinding

Eligible patients will be randomly allocated to the intervention and control groups by REDCap. Randomization sequences will be generated by using the big stick design [34]. Trial participants and outcome assessors will be blinded. In addition, the data analyst will have access to the anonymized datasheet, without being aware of the allocated intervention. Dark, uniformly packaged, sealed bottles of mouthwash labeled A and B will contain the assigned interventions, which will be given to patients after the randomization. A dental hygienist, who will not be involved in the assessments of the outcomes, will hand out the boxes with the assigned mouthwashes to the participants and supervise the rinsing process. The examiner will examine the patients in a separate room from rinsing without knowing their assigned intervention. The information in an opaque envelope about which mouthwashes are A and B will be kept in the safe of the guarantor of the trial.

Data collection, management, and analysis

Data collection methods and data management

The required data will be collected using prespecified electronic case report forms (REDCap) [35]. The principal investigator of the trial (ES) will anonymously handle and store participant data on a server for at least twenty years. Data collection forms can be found in Supplementary Documents1.

Any data modifications will be recorded and checked by the statistician and the guarantor of the trial. Any missing or incorrect data will be reported by the statistician; and the data quality check module of REDCap will also be applied.

Statistical methods

We will report on baseline characteristics and differences between the two arms. For continuous primary and secondary endpoints, we will report the mean results of the groups and changes at the different time points. Due to the non-inferiority study design, we choose the non-inferiority limit (d = 1) as the most considerable clinically acceptable difference. For the side-effect questionnaire, we will create a summary table showing the frequency of adverse events and all patient comments. In the case of any missing data, sensitivity analyses will be conducted to determine the most suitable approach.

Monitoring

Data monitoring

The size and length of the trial make a data monitoring committee unnecessary. A statistician (PHá) and a clinical research specialist (BT), independent of the sponsor and the trial, will monitor data.

Safety and adverse events

Side effects of chlorine dioxide at this low concentration are not known yet [28]. Prolonged use of CHX-containing mouthwash can lead to several adverse events with a relatively high frequency and it is hypothesized that a specific type of control mouthwash may have fewer undesirable effects [12]. We will ask the patients about their experiences at each time point. If patients experience any adverse events, we will record these follow-up questionnaires. SC will verify the validity of adverse events; the relevant ones will be reported to the National Institute of Pharmacy and Nutrition (OGYÉI). If any safety concerns arise, we will stop the study immediately.

Withdrawal from study

Due to the length of the study, we expect a small number of eligible participants to withdraw or drop out. Previous studies [36,37,38] have reported a dropout rate of 10%.

Public and patient involvement

The protocol development phase involved three patients. We asked them to read the patient information leaflet and give informed consent after being introduced to the purpose, primary outcome, and protocol of the study. They thought that the written materials were transparent and informative. Our clinical question was deemed highly relevant by the patients. They said that the one-day caffeine restriction was too long, and that they could not imagine not brushing their teeth the night before the investigation. Thus, we reduced the time limits in the protocol, oral hygiene restriction from 12 to 8 h, and caffeine from one day to the day of the investigation. In addition, they expressed their preference for flavored mouthwashes.

Dissemination

Protocol amendments

Any potential deviation from the protocol will be discussed with the SC. If the team accepts the changes, they will be reported in the protocol registration and the final article with the data.

Publication policy

We plan to publish our results regardless of the results and the feasibility of the more extended version.

Strengths

• The efficacy of hyperpure chlorine dioxide has not been investigated in the therapy of intra-oral halitosis yet.

• Gas chromatography calibrated with a standardized gas mixture will be used to assess halitosis.

• This study can be the basis for more extended studies.

Limitations

• The long-term oral effects of hyperpure chlorine dioxide will not be monitored.

• First, 30 people each will be enrolled in two groups, then a sample size estimation will follow (lack of data on the intervention did not allow the sample size calculation). This will be a pilot study.

Funding

This study was supported by the Faculty of Dentistry (Semmelweis University, Budapest, Hungary, NR: 20093-2/FOFTO/2023) and by the Department of Restorative Dentistry and Endodontics (Semmelweis University, Budapest, Hungary). Funding was provided by the ÚNKP-22-3 New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund (to BT - ÚNKP-23-3-II-PTE-1996). Open access funding provided by Semmelweis University.

Authors and Affiliations

1. Department of Restorative Dentistry and Endodontics, Semmelweis University, Budapest, Hungary

   Eszter Ágnes Szalai,Zsolt M. Lohinai&Beáta Kerémi

2. Centre for Translational Medicine, Semmelweis University, Budapest, Hungary

   Eszter Ágnes Szalai,Brigitta Teutsch,Péter Hegyi,Gábor Varga,Zsolt M. Lohinai&Beáta Kerémi

3. Department of Radiology, Medical Imaging Centre, Semmelweis University, Budapest, Hungary

   Brigitta Teutsch

4. Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary

   Brigitta Teutsch&Péter Hegyi

5. Faculty of Dentistry, Semmelweis University, Budapest, Hungary

   Viktória Babay&Adél Galvács

6. Division of Pancreatic Diseases, Semmelweis University, Budapest, Hungary

   Péter Hegyi

7. University of Veterinary Medicine Budapest, Department of Biostatistics, Budapest, Hungary

   Péter Hársfalvi

8. BiTrial Clinical Research, Budapest, Hungary

   Péter Hársfalvi

9. Today Science Ltd., Diósd, Hungary

   Róbert Pál

10. Department of Oral Biology, Semmelweis University, Budapest, Hungary

    Gábor Varga

Contributions

ES: Conceptualization, Funding acquisition, Investigation, Writing – original draft; BT: Conceptualization, Methodology, Supervision, Project administration, Writing – review & editing; VB: Writing – review & editing; AG: Writing – review & editing; PH: Conceptualization, Supervision; and Writing – review & editing; PHá: Data curation, Formal Analysis, Supervision; RP: Writing – review & editing; GV: Writing – review & editing; ZML: Conceptualization, Supervision, Writing – review & editing; BK: Conceptualization, Supervision, Writing – review & editing. All authors provided critical conceptual input and approved the final version of the article.

Corresponding author

Correspondence to Beáta Kerémi.

Competing interests

The authors declare no competing interests.

Ethics approval

The protocol has been approved by the National Institute of Pharmacy and Nutrition (OGYÉI) (838). The study will be performed following the declaration of Helsinki (International Conference on Harmonization and Good Clinical Practice guidelines). All eligible participants will receive verbal and written information about the objectives and products of the study before being asked to sign an electronic informed consent form. Participants will have the opportunity to ask the medical personnel any questions that may arise and refuse to participate. After signing the Hungarian version of the Study Participation Consent Form and Patient Information Leaflet, eligible participants will be randomized on the electronic platform (REDCap (Research Electronic Data Capture)). Project team members will have access solely to the blinded data, which will be handled confidentially.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions